Related Experiment Video
Updated: Sep 26, 2025
11:20
Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
Published on: March 29, 2018
7.7K
Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition
Hezi Hayun1,2, Valeria Arkadash1,2, Amiram Sananes1,2
1Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, P.O. Box 653, Beer-Sheva 84105, Israel.
Bioconjugate Chemistry
|April 21, 2022
Summary
This study engineered tissue inhibitor of metalloproteinase 2 (TIMP2) for improved therapeutic potential. Site-specific PEGylation using a noncanonical amino acid extended its half-life without compromising MMP-14 inhibitory activity.
Area of Science:
- Biochemistry
- Protein Engineering
- Pharmacology
Background:
- Matrix metalloproteinases (MMPs), particularly MMP-14, regulate extracellular matrix and are implicated in diseases like cancer.
- Tissue inhibitors of metalloproteinases (TIMPs) inhibit MMPs, but TIMP2 has limitations as a therapeutic due to degradation and short half-life.
Purpose of the Study:
- To engineer TIMP2 for enhanced therapeutic efficacy against MMP-14.
- To overcome limitations of traditional PEGylation by developing a site-specific modification strategy.
Main Methods:
- Incorporation of a noncanonical amino acid, propargyl lysine (PrK), at position S31 of N-TIMP2.
- Site-specific mono-PEGylation of N-TIMP2-S31PrK using click chemistry with PEG-azide-20K.
- Assessment of MMP-14 inhibitory activity, serum stability, and in vivo pharmacokinetics.
Main Results:
- Site-specific PEGylation retained N-TIMP2's inhibitory activity against MMP-14.
- PEGylated N-TIMP2 exhibited improved serum stability compared to the non-PEGylated form.
- In vivo studies showed an 8-fold increase in the elimination half-life of PEGylated N-TIMP2 in mice.
Conclusions:
- Site-specific bioorthogonal mono-PEGylation is an effective strategy to enhance the pharmacokinetic profile of TIMP2.
- This approach extends the therapeutic half-life of N-TIMP2 without sacrificing its biological activity.
- The engineered PEGylated TIMP2 demonstrates potential as a therapeutic agent for MMP-14-related diseases.
